Completed PHASE2 INTERVENTIONAL 4-arm NCT04345900

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

A Phase 2, Multicenter, Randomized Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)

Sponsor: BeyondSpring Pharmaceuticals Inc.

Conditions Chemotherapy-induced Neutropenia

Interventions Pegfilgrastim Plinabulin

Updated 6 times since 2020 Last updated: May 7, 2024 Started: Apr 5, 2017 Primary completion: Mar 20, 2018 Completion: Apr 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chemotherapy-induced Neutropenia, this trial is completed. The trial is conducted by BeyondSpring Pharmaceuticals Inc. and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2024 [monthly]

Completed PHASE2

▶ Show 1 earlier version

May 2020 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeyondSpring Pharmaceuticals Inc.

Data source: BeyondSpring Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Dnipro, Ukraine , Dublin, United States , Harbin, China , Ivano-Frankivsk, Ukraine , Kherson, Ukraine , Krivói Rog, Ukraine , Kropyvnytskyi, Ukraine , Kyiv, Ukraine , Lviv, Ukraine , Nanjing, China and 9 more locations